Detail akcie Nektar Therap online

Business Summary: Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Nektar Therapeutics revenues decreased 9% to $70M. Net loss decreased 18% to $308.5M. Revenues reflect Non-cash royalty revenue related to the decrease of 11% to $52.2M, Product sales decrease of 10% to $16M. Lower net loss reflects Research and development - Balancing val decrease of 38% to $161.4M (expense), Change in fair value of development deri increase from $7.6M (expense) to $33.4M (income).